Just in December, six companies have announced the launch of their denosumab biosimilars in Europe: Sandoz, Samsung Bioepis, Fresenius Kabi, ...

The role of the ocular oncologist is two-fold: he must establish the correct diagnosis and then institute the appropriate therapy, if required. Prior to the establishment of ocular oncology as a ...

BCVA is inadequate for detecting visual disturbances in conditions like MacTel, which initially affect the parafoveal region.

Architectural eyewear to airports, imaging and testing equipment. OT gathers product news from the last 60 days ...

Chugai Pharma announces 48-week NIHONBASHI phase III study results presented at JRVS meeting show that Vabysmo sustained vision improvements in Japanese patients with angioid streaks ...

European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

Rejecting the proposal for a clinical trial waiver for Atropine Sulphate Ophthalmic Solution IP 0.025% w/v, the Subject ...

A 55-year-old white man with a medical history of well-controlled type 2 diabetes, rheumatoid arthritis and fibromyalgia ...

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and ...

Caregen to release US phase 1 results for eyedrop CG-P5 against Eylea Caregen to reveal delayed phase 1 eyedrop data for ...

Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for BYOOVIZ (ranibizumab) pre-filled syringe (PFS) PFS presentation to become ...